The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.
C07K 16/36 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de coagulation sanguine
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention relates to a method for directing differentiation of neural cells into neurons by obtaining a cell population comprising neural cells and contacting the cell population with an inhibitor of NOTCH signaling, wherein the inhibitor of NOTCH signaling is selected from LY411575, Avagacestat, Dibenzazepine, and PF-03084014.
The present invention provides ISVD polypeptide derivatives capable of binding coagulation Factor IX(a) and Factor X(a) which are highly potent and provide a sufficiently long half-life such to allow for effective subcutaneous—as well as peroral administration. The ISVD polypeptides derivatives disclosed herein are thus suitable for treatment of haemophilia A, haemophilia A with inhibitors and acquired haemophilia A by various routes of administration including subcutaneous and peroral administration.
The present invention is in the field of pharmaceutical compositions for the treatment of medical conditions relating to diabetes. More specifically the invention provides pharmaceutical compositions comprising a long-acting acylated derivative of a human insulin analogue, and to the medical use of such compositions for basal insulin administration therapy.
The present invention is directed to use of the GLP-1 receptor agonist semaglutide in medical therapy for the treatment of heart failure with preserved ejection fraction (HFpEF).
The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising a stabilizer such as histidine, their preparation, kits comprising such compositions as well as medical uses thereof.
Disclosed herein is a preserved liquid pharmaceutical formulation comprising an amylin receptor agonist, a GLP-1 receptor agonist, a cyclodextrin comprising hydroxypropyl substitutions and one or more preservatives. Said co-formulation may be used for the medical treatment of subjects with overweight or obesity, with or without associated co-morbidities; diabetes, with or without associated comorbidities; and cardiovascular diseases.
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 38/00 - Préparations médicinales contenant des peptides
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of diabetes;
pharmaceutical preparations for weight reduction and long
term weight loss maintenance; pharmaceutical preparations
for the treatment of cardiovascular diseases.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of diabetes;
pharmaceutical preparations for weight reduction and long
term weight loss maintenance; pharmaceutical preparations
for the treatment of cardiovascular diseases.
The invention relates to fusion proteins comprising a GLP-1 polypeptide and an FGF21 polypeptide separated by spacers. The invention also relates to fusion compounds comprising the fusion proteins and at least one substituent. The invention also relates to the pharmaceutical use of the fusion compounds.
A drug delivery assembly comprising a drug delivery device and a thereon mountable needle unit. The needle unit comprises a needle hub with a hollow needle having a pointed distal end protruding from the needle hub, and a shield in which the needle hub is fully or partly arranged, the shield being axially moveable relative to the needle hub between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield. The needle unit further comprises coupling means allowing the needle unit to be mounted on the drug delivery device, the coupling means being actuatable between (i) a lock state in which a mounted needle unit cannot be removed from the drug delivery device, and (ii) an actuated release state in which the needle unit can be removed from the drug delivery device.
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
A61M 5/34 - Structures pour le raccordement de l'aiguille
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
A drug delivery assembly comprising a drug-filled cartridge, an actuatable drug-expelling mechanism, a needle hub with a needle protruding from the needle hub, and a shield in which the needle hub is fully or partly arranged, the shield being axially moveable relative to the needle hub between an extended position in which the shield axially covers the needle, and a retracted position in which the needle protrudes from the shield corresponding to a needle free length. The shield is mounted non-rotatable relative to the housing, the needle hub being rotatable relative to the shield and thus to the housing. The needle hub is rotated relative to the shield when the shield is moved from its retracted to its extended position, wherein rotational movement of the needle hub takes place after at least half of the needle free length has been covered by the shield.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
A61M 5/34 - Structures pour le raccordement de l'aiguille
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
16.
SHIELDED NEEDLE UNIT WITH ACTUATABLE MOUNTING FEATURE
A drug delivery assembly comprising a drug delivery device and a thereon mountable needle unit. The needle unit comprises a needle hub with a hollow needle having a pointed distal end protruding from the needle hub, and a shield in which the needle hub is fully or partly arranged, the shield being axially moveable relative to the needle hub between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield. The needle unit further comprises coupling means allowing the needle unit to be mounted on the drug delivery device, the coupling means being actuatable between an initial mounting state in which the needle unit can be mounted on the drug delivery device, and a lock state in which a mounted needle unit cannot be removed from 10 the drug delivery device.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
A61M 5/34 - Structures pour le raccordement de l'aiguille
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
17.
SHIELDED NEEDLE UNIT WITH ACTUATABLE CONTAINER COUPLING
A needle assembly comprising a needle unit and a container therefor. The needle unit comprises a needle hub in which a distally protruding needle is mounted, and a shield in which the needle hub is arranged. The shield is axially moveable between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield, as well as coupling means allowing the needle unit to be mounted on a drug delivery device. The assembly comprises a snap coupling between the container and the shield, the snap coupling being actuatable between an engaged first state in which the needle unit can be removed from the container using a first amount of force, and a second engaged state in which the needle unit can be removed from the container using a second higher amount of force.
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
A61M 5/34 - Structures pour le raccordement de l'aiguille
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras
18.
DRUG DELIVERY ASSEMBLY WITH DOUBLE-DOSE PREVENTION
A drug delivery assembly comprises a drug delivery device and a thereon mountable needle unit. The drug delivery device comprises an actuatable spring-driven expelling mechanism for expelling an amount of drug. The needle unit comprises a shield in which a hub with a needle is arranged, the shield being axially moveable relative to the hub between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield. Shield locking means is actuated when the shield is moved from the retracted to the extended position, the actuated shield locking means pre- venting retraction of the shield. The shield is adapted to actuate the expelling mechanism ac- tuation means when the shield is moved from the extended position to the retracted position, whereby double-actuation of the expelling mechanism with the same needle unit mounted is prevented.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
A61M 5/34 - Structures pour le raccordement de l'aiguille
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A drug delivery assembly comprising a drug delivery device and a thereon mountable needle unit. The needle unit comprises a shield in which a needle hub with a needle is arranged, the shield being axially moveable between an extended position in which the shield axially covers the needle distal end, and a retracted position in which the needle distal end protrudes from the shield, the shield comprising a proximal skirt portion. The drug delivery device comprises a circumferential space adapted to receive the shield. The circumferential space and the shield skirt portion have corresponding non-circular configurations allowing the shield skirt portion to be axially received in the circumferential space in one or more pre-determined rotational mounting positions. Corresponding coupling means on the hub respectively the drug delivery device allows needle unit to be mounted on the drug delivery device in any of the pre-determined rotational positions.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
A61M 5/34 - Structures pour le raccordement de l'aiguille
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
20.
METHOD FOR PROVIDING A CELL POPULATION ENRICHED IN NEURONS AND PRECURSORS THEREOF
The present invention relates to a method for providing a cell population enriched in neurons and/or precursors thereof, comprising the steps of obtaining a cell population comprising neuron precursors, and selecting cells positive indicative of whether a cell has high propensity for developing into a neuron.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
21.
LONG-ACTING GROWTH HORMONE RECEPTOR ANTAGONIST AND USE THEREOF
The invention relates to a long-acting growth hormone receptor antagonist comprising a growth hormone variant and an albumin binding moiety. Further described are methods of preparing said compound and use thereof in medicine e.g., for the treatment of acromegaly.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 38/27 - Hormone de croissance [GH] (Somatotropine)
A61P 5/02 - Médicaments pour le traitement des troubles du système endocrinien des hormones hypothalamiques, p.ex. TRH, GnRH, CRH, GRH, somatostatine
22.
AUTOMATIC INJECTION DEVICE WITH A TOP RELEASE MECHANISM
The present invention relates to a handheld mechanical injection device by which set doses of a liquid medicament can be injected from a medical reservoir. The medicament is expelled through an injection needle by release of a power reservoir in the device, the power reservoir being fully or partially released by actuation of a user operable release member being positioned at or near an upper end of the injection device, the upper end being that end of the injection device which is opposite the injection needle.
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
The present invention provides a dose delivery device (1, 100, 200, 300, 400) comprising: a variable volume reservoir (10, 110, 210, 310, 410) holding a pharmaceutical suspension and comprising an outlet (12, 112, 212, 312, 412), a dose expelling mechanism adapted for activation to expel a volume of the pharmaceutical suspension through the outlet (12, 112, 5 212, 312, 412), and a dose preparation system comprising a preparation member (30, 130, 230, 330, 430) operable prior to activation of the dose expelling mechanism to enable administration of the volume of the pharmaceutical suspension to a subject, wherein the dose preparation system further comprises an agitation member (40, 140, 240, 340, 440) capable of agitating relative motion with respect to the variable volume reservoir (10, 110, 210, 310, 10 410), the agitating relative motion causing a re-suspending agitation of the pharmaceutical suspension, and wherein the agitation member (40, 140, 240, 340, 440) is operatively coupled with the preparation member (30, 130, 230, 330, 430) and configured to undergo said agitating relative motion in response to the operation of the preparation member (30, 130, 230, 330, 430).
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
The present invention relates to novel insulin derivatives and their use in the treatment or prevention of medical conditions relating to diabetes. The insulin derivatives are glucose sensitive and display glucose-sensitive albumin binding. The insulin derivatives have a long half-life. The invention also relates to novel intermediates. Finally, the invention provides a pharmaceutical composition comprising the insulin derivatives of the invention and the use of such a composition in the treatment or prevention of medical conditions relating to diabetes.
An ingestible device may include one or more deployable limbs configured to orient the ingestible device in a desired orientation. The one or more limbs may be attached to body of the device and wrap around the device in an initial configuration (e.g., prior to deployment of the one or more limbs). The one or more limbs may be configured to deploy when exposed to a predetermined condition. Once the predetermined condition is met, the one or more limbs may extend outwards away from the body such that the one or more deployed limbs serve to orient the ingestible device.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for weight reduction and long term weight loss maintenance; pharmaceutical preparations for the treatment of cardiovascular diseases.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for weight reduction and long term weight loss maintenance; pharmaceutical preparations for the treatment of cardiovascular diseases.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of diabetes; Pharmaceutical preparations for weight reduction and long term weight loss maintenance; Pharmaceutical preparations for the treatment of cardiovascular diseases..
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of diabetes; Pharmaceutical preparations for weight reduction and long term weight loss maintenance; Pharmaceutical preparations for the treatment of cardiovascular diseases..
31.
COMPOSITIONS AND METHODS FOR SITE-DIRECTED MUTAGENESIS
The present disclosure provides improved genome editing compositions and methods for editing a double-strand DNA target site. The disclosure further provides genome edited cells produced by the compositions and methods described.
The invention relates to a tablet comprising a salt of N-(8-(2-hydroxy benzoyl)amino)caprylic acid. The invention further relates to processes for the preparation such a tablet, and its use in medicine.
The invention relates to fusion proteins comprising a GLP-1 polypeptide and an FGF21 polypeptide separated by spacers. The invention also relates to fusion compounds comprising the fusion proteins and at least one substituent. The invention also relates to the pharmaceutical use of the fusion compounds.
The invention relates to a method of identifying one or more caudal ventral midbrain (cVM) progenitor cells by measuring the presence and/or amount of adenomatosis polyposis coli down-regulated 1 (APCDD1) expressed by the one or more cells. The invention also provides methods of enriching cVM cells, uses of said cells in the treatment of disease, use of APCDD1 as a biomarker, and kits.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
A capsule device (100), comprising: a) a capsule housing (110, 120) having proximal and distal ends and defining a main axis, the capsule housing comprising a plurality of retainer portions (113a) distributed around the main axis, and b) an actuation mechanism (140, 150) operable between a pre-actuation configuration and an actuating configuration, wherein the actuation mechanism (140, 150) comprises: b1) an actuation member (150) configured for axial distal movement, the actuation member (150) comprising a base portion (151) and a plurality of radially deflectable latch arms (153) extending proximally therefrom, wherein each latch arm (153) defines a radially inwards facing latch surface (153b) being inclined with respect to the axis and a radially outwards facing latch surface (153a) in retaining engagement with a respective retainer portion (113a) of the capsule housing (110, 120), b2) a drive spring (140) exerting mechanical load onto the actuation member (150) for driving the actuation member axially in the distal direction, and b3) a dissolvable latch support (160) having radially outwards facing surfaces (163b) being inclined relative to the axis, wherein the dissolvable latch support (160) is arranged centrally on-axis and wherein the plurality of radially deflectable latch arms (163) are distributed around the main axis so that each latch arm (163) is releasably retained radially between a respective one of said inclined outwards facing surfaces (163b) of the dissolvable latch support (160) and a respective one the retainer portions (113a).
A drug delivery device (100, 300) for delivering a medicament, wherein the device comprises an insertion controlled needle cannula (224, 424), wherein the drug delivery device comprises: a retaining structure (130, 136, 350, 430) axially locked to the housing and adapted for retaining the hub (225, 425) in the proximal position, a pulling structure (230, 320) axially locked to the shield (110, 310) and adapted for being disengaged from the hub (225, 425), in a decouple state, whereby the pulling structure is movable relative to the hub (225, 425), and wherein the pulling structure (230, 320) is further adapted for engaging the hub, in a coupled state, whereby the pulling structure is movable together with the hub, wherein the retaining structure and the pulling structure are operatively connected to the shield (110, 310) and the needle assembly (220, 420) in the active position. Thereby, the drug delivery device provides a needle insertion sequence control mechanism ensuring that the distal end of the cannula is covered before the proximal end of the cannula is pulled out from the reservoir.
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
41.
Combination Therapy for Treatment of Liver Disease
The present disclosure relates to a method of treating non-alcoholic steatohepatitis (NASH) comprising administering to a subject with NASH a combination therapy comprising semaglutide, firsocostat, and/or cilofexor.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
42.
COMPOSITIONS AND METHODS FOR INHIBITING TRANSMEMBRANE SERINE PROTEASE 6 (TMPRSS6) EXPRESSION
Oligonucleotides are provided herein that inhibit TMPRSS6 expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with hepcidin deficiency or suppression.
The invention concerns a process for preparing a pharmaceutical formulation comprising an insulin derivative, wherein the process comprises dissolving an insulin derivative in water, adjusting the pH of the solution to a pH above 7.2, adding a zinc solution while stirring continuously and adjusting the pH to the target pH of the formulation.
A drug delivery device (100, 300) for delivering a plurality of doses of a medicament, wherein a needle shield (110, 310) is operationally coupled to a hub driving structure (210, 430), a active needle assembly (220, 420), a pulling structure (230, 320) and a support structure (136, 336, 338, 350) such that the operation of the needle shield is adapted to drive the active needle assembly (220, 420) to the proximal position of the active needle assembly (220, 420), before the needle shield (110, 310) can reach the proximal position of the needle shield (220, 420), whereby fluid connection can be establish before the drive mechanism can be activated.
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
1. A drug delivery device (100) comprising: a) a drug chamber (B) configured to accommodate a drug substance, the drug chamber (B) leading to a drug delivery opening (195), b) an actuation chamber (A), c) a gas generator (140, 142) configured for being actuated to generate pressurized gas in the actuation chamber (A) for exerting mechanical load on the drug substance in the drug chamber (B) to thereby cause delivery of the drug substance through the drug delivery opening (195), and d) a trigger arrangement (170, 180, 129) initially preventing the pressurized gas from said delivery but allowing said delivery upon gas pressure in the actuation chamber (A) reaching a threshold gas pressure level, wherein the trigger arrangement comprises: d1) a trigger member (170) arranged for displacement from a low-pressure position to a high-pressure position, and d2) a compliant device (180) providing a gradually increasing counter force on the trigger member (170) as the trigger member moves from the low-pressure position to the high-pressure position, wherein the trigger member (170) is adapted to move, due to generated gas, from the low-pressure position in which no mechanical load is exerted by pressurized gas to cause delivery of the drug substance to the high-pressure position in which said mechanical load is allowed to cause delivery of the drug substance through the drug delivery opening (195).
A system comprising RGB and UV light emitting means and RGB light sensor means adapted to measure and differentiate between colours having a given minimum colour difference, as well as first and second colour identifiers having a colour difference below the minimum. One of the colour identifiers comprises a light transforming component adapted to emit additional RGB light when subjected to UV light emitted by the UV light emitting means providing an enhanced RGB colour difference above the minimum colour difference between the RGB light emitted from the first and second colour identifiers when subjected to the combined light from the RGB and UV light emitting means, this allowing the RGB light sensor means to differentiate between the colours of the first respectively the second colour identifier.
G01J 3/46 - Mesure de couleur; Dispositifs de mesure de couleur, p.ex. colorimètres
G01N 21/00 - Recherche ou analyse des matériaux par l'utilisation de moyens optiques, c. à d. en utilisant des ondes submillimétriques, de la lumière infrarouge, visible ou ultraviolette
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
47.
SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A
The present invention relates to a method of making sodium N-(8-2-Hydroxybenzoyl)amino capry late form A. SNAC polymorphic form A having improved stability and the use of said SNAC polymorphic form A in a solid pharmaceutical dosage form
C07C 235/60 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés à des atomes de carbone du même cycle aromatique à six chaînons non condensé avec des atomes de carbone de groupes carboxamide et des atomes d'oxygène, liés par des liaisons simples, liés en position ortho à des atomes de carbone du même cycle aromatique à six chaînons non condensé ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques
A capsule administering assembly (100, 100′) comprising an ingestible capsule (200, 200′) for delivery of a mixed drug product to a subject user, and a capsule accessory device (300, 300′), wherein the ingestible capsule is operable from a first attached state where the ingestible capsule (200, 200′) is coupled relative to the capsule accessory device (300, 300′), and a second detached state wherein the ingestible capsule (200, 200′) is detached from the capsule accessory device (300, 300′) to permit ingestion of the ingestible capsule. The capsule administering assembly (100, 100′) comprises a first reservoir (231) holding a first drug component (A) and a second reservoir (332, 362), the second reservoir (332, 362) holding a second drug component (B).
The invention relates to a pre-filled single dose injection device expelling one single dose of a predetermined fixed volume with an embedded cartridge wherein a piston rod has a predetermined travel distance and wherein the position of the travel distance of the piston rod relatively to a housing structure securing the cartridge is individually adjustable for each individual injection device.
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
The invention relates to a compound comprising a GLP-1 receptor agonist and an amylin receptor agonist. The invention also relates to a pharmaceutical formulation, suitable for but not limited to oral administration, which comprises such a compound. The compound and pharmaceutical formulation comprising it may be used for the medical treatment of subjects with overweight, obesity and associated co-morbidities.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
A self-righting ingestible capsule comprising: a) a capsule housing (110, 120) defining a central axis and having proximal and distal ends, b) a sealing compartment (A) within the capsule housing (110, 120) accommodating a solid dose member (130), and comprising a distal exit port (124), c) an actuation compartment (B) fluidically isolated from the scaling compartment (A), d) an actuation member (150) at least partially accommodated in the actuation compartment (B) and arranged for axial displacement thereby moving the dose member (130) distally through the distal exit port (124), e) a helical spring (140) for powering the actuation member (150) in a distal direction, f) a latch component (152) coupled to the actuation member (150) for releasably maintaining the actuation member latched in a proximal position, and g) a dissolvable latch support (160) disposed in the actuation compartment (B), wherein the dissolvable latch support maintains latching of the actuation member (150) in the proximal position by supporting the latch component
A method of estimating insulin on board (IOB) for a given glucose sensitive insulin (GSI) in a subject is provided. The method comprises the steps (i) for the given GSI, providing at least one rate constant (rc) as function of glucose concentration (rc(G)), (ii) providing for a period of time a continuous blood glucose log G(t) from the subject, (iii) providing for the period of time 5 an insulin dose log I(t) from the subject, (iv) based on rc(G) and G(t), calculating for each rc a rate constant as function of time (rc(t)), and (v) based on the at least one rc(t) and I(t) and using an estimating algorithm, calculating an estimated IOB for the subject.
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
The invention relates to a compound comprising an amylin receptor agonist. The invention also relates to a pharmaceutical composition, suitable for but not limited to oral administration, which comprises such a compound. The compound and pharmaceutical composition comprising it may be used for the medical treatment of subjects with overweight, obesity and associated co-morbidities.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
The present invention concerns human antibodies recognising the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present disclosure relates to improved therapeutic RNA compositions. More particularly, the disclosure relates to improved methods for purifying therapeutic RNA and related therapeutic RNA preparations.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
This application relates to new C-type natriuretic peptide (CNP) compounds, pharmaceutical compositions comprising these compounds, and these compounds for use as medicaments.
The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
78.
METHOD FOR LARGE-SCALE BANKING OF HUMAN PLURIPOTENT STEM CELLS AND PRODUCTS DERIVED THEREOF
The present invention relates to a method for establishing a cell bank, comprising the steps of providing a batch of cell suspension comprising stem cells or stem cell-derived cells, and a cryopreservation medium, maintaining the batch of cell suspension at a temperature below 15° C., and transferring an amount of the cell suspension from the batch of cell suspension into one or more storage containers, wherein establishing the cell bank takes at least (30) minutes.
A method responsive to receiving a request for an estimated FBG value. The method com- prises the steps of (i) obtaining a CGM data set from a subject for a given time period, the CGM data set comprising a plurality of BG values determined over the time period, (ii) obtaining an identifier percentile representing the given demographic, the given drug treatment regimen, 5 and the given time period being representative of the subject, and (iii) estimating the FBG value as the identifier percentile of the CGM data set.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
G16H 20/60 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant le contrôle de l’alimentation, p.ex. les régimes
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p.ex. pour analyser les cas antérieurs d’autres patients
80.
NK CELL ACTIVATING RECEPTOR LIGAND KNOCKOUTS FOR USE IN CELL THERAPY
The technical field of the present invention is cell therapy, more particularly cell replacement therapy. The invention relates to a cell comprising on its cell surface no fully functional form of at least one protein selected from the list consisting of ULBP-2, CD112, CD155, B7-H3, ULBP-3, ULBP-4, ULBP-5, ULBP-6, B7-H6, B7-H7, MICA, MICB, CD48, CD58, CD70, CD1d, CD318, TRAIL-R1 and TRAIL-R2. The invention also relates to cell compositions and uses thereof.
The invention relates to a compound comprising an amylin receptor agonist. The invention also relates to a pharmaceutical composition, suitable for but not limited to oral administration, which comprises such a compound. The compound and pharmaceutical composition comprising it may be used for the medical treatment of subjects with overweight, obesity and associated co-morbidities.
The present invention relates to a chemical process for the synthesis of the compound 8-[(2-hydroxybenzoyl)amino]octanoic acid or a derivative thereof useful in the process of making sodium 8-[(2-hydroxybenzoyl)amino]octanoate (SNAC), a delivery agent used in solid pharmaceutical compositions. The invention provides an efficient synthesis using less hazardous chemicals and/or a reproducible process that is easier to handle on production scale.
C07C 231/02 - Préparation d'amides d'acides carboxyliques à partir d'acides carboxyliques ou à partir de leurs esters, anhydrides ou halogénures par réaction avec de l'ammoniac ou des amines
The invention relates to a drug delivery system which essentially comprises three major components: a housing structure (10), a reservoir structure (20) and a protective cap structure (30). The housing structure comprises an electronic dose size capture arrangement and first communicating means. The reservoir structure contains the liquid drug and is releasable attachable to the housing structure. The reservoir structure further comprises an identifier which is coded with information relating to the type of drug contained in the reservoir structure. The protective cap, which is mountable on the drug delivery device comprises a sensor arrangement configured to sense the information coded in the identifier and second communication means for communicating the information regarding the type of drug contained in the reservoir structure.
A61M 5/20 - Seringues automatiques, p.ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
A61M 5/24 - Seringues à ampoules, c. à d. seringues à aiguille utilisables avec des ampoules ou des cartouches échangeables, p.ex. automatiques
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
84.
PCSK9 ENDONUCLEASE VARIANTS, COMPOSITIONS, AND METHODS OF USE
The present disclosure provides improved genome editing compositions and methods for editing a PCSK9 gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of hypercholesterolemia or a condition associated therewith.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 9/64 - Protéinases provenant de tissu animal, p.ex. rennine
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
The present invention relates to novel peptides that are derivatives of glucose-dependent insulinotropic polypeptide (GIP) analogues having improved physical stability in solution and a protracted profile of action. More particular the invention relates to such peptides that are agonists at the GIP receptor and to their use in weight management or for treatment of diseases such as obesity, diabetes or non-alcoholic steatohepatitis (NASH).
A capsule device (200) suitable for ingestion into a lumen of the gastrointestinal tract of a patient, the capsule device (200) configured as a self-righting capsule comprising: a) a capsule housing (210, 220) comprising a compartment and an exit opening (224), b) a tissue penetrating member (230, 260, 270), and c) an actuator arrangement (240, 250) configured to move the tissue penetrating member (230, 260, 270) into the lumen wall at a target location. The actuator arrangement (240, 250) comprises a drive spring (240) with a first (240a) and a second helical portion (240b) being wound about at least a portion of the first helical portion (240a), wherein a transitional portion of the second helical portion (240b) connects to a transitional portion of the first helical portion (240a). One of the helical portions (240a, b) acts as a tension spring and the other as a compression spring.
An ingestible device for swallowing into a lumen of a gastrointestinal tract and for insertion into a lumen wall, the ingestible device (100) comprising: a) a housing (110, 120) with an exit opening (124), b) a tissue interfacing component (160, 170) configured for being advanced axially from a first position wherein it's first end does not protrude from the exit opening (124) and into a second position wherein the first end protrudes from the exit opening (124) for insertion in the lumen wall at a target location, c) an actuator arrangement (140, 150) for advancing the tissue interfacing component (160, 170) from the first position to the second position, and d) a shielding arrangement (131) for shielding the tissue interfacing component (160, 170) and configured by shifting from a non-shielding configuration to a shielding configuration subsequent to the tissue interfacing component (160, 170) entering into the second position.
Disclosed herein are compositions comprising a GLP-1 peptide and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid for use as a medicament by oral administration.
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 31/20 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique
This application relates to new C-type natriuretic peptide (CNP) compounds, pharmaceutical compositions comprising these compounds, and these compounds for use as medicaments.
A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes
The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
1. A drug delivery device for delivering a plurality of fixed doses of a medicament, wherein the drug delivery device comprises a needle magazine with a plurality of needle assemblies, a needle positioning mechanism, a drive mechanism for delivering a fixed dose of the plurality of fixed doses, in response to activation, an activation mechanism for activating the drive mechanism comprising a movable shield (110, 310), wherein the shield (110, 310) is adapted to activate the drive mechanism, in response moving the shield to the proximal position. The drug delivery device further comprises a drop lock mechanism comprising a non-blocking state and a blocking state.
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
99.
DRUG DELIVERY DEVICE FOR DELIVERING A PREDEFINED FIXED DOSE
A drug delivery device (100, 300) for delivering a plurality of fixed doses, comprising a drive mechanism with a prestrained drive spring (108) for sequentially expelling the plurality of fixed doses, and an activation mechanism comprising an axially movable activation assembly (110, 310) for activating the drive mechanism to expel a fixed dose, and user operable for activation as a first user operation. The device further comprises a double dose prevention mechanism adapted to shift from a non-blocking to a blocking state after the first user operation of activating the activation mechanism, and adapted to shift from the blocking to the nonblocking state, in response to the second user operation of operating the unlocking structure.
A61M 5/315 - Pistons; Tiges de piston; Guidage, blocage, ou limitation des mouvements de la tige; Accessoires disposés sur la tige pour faciliter le dosage
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61M 5/32 - Seringues - Parties constitutives - Parties constitutives des aiguilles relatives au raccordement de celles-ci à la seringue ou au manchon; Accessoires pour introduire l'aiguille dans le corps ou l'y maintenir; Dispositifs pour la protection des aiguilles
A61M 5/50 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaire; Accessoires à cet effet, p.ex. dispositifs de remplissage ou de nettoyage, appuis-bras avec des moyens pour empêcher la réutilisation ou pour indiquer si le dispositif est défectueux, usagé, non stérile ou si l'on a tenté de l'utiliser
